These results are important as they represent the first pharmacological tool to amplify BCR-ABL-expressing primary leukemic cells in patients with CML, a goal which has been achieved previously only by the use of gene transfer techniques using NUP98-HOXA10 gene fusion transduced to CML progenitors [27]. This evidence concerns the gene NUP98 and chronic myelogenous leukemia, BCR-ABL1 positive.